Commercialization and Development Pipeline for New Functional Materials
First written in FY2016-Q3. 23 of 29 entries say "Advanced", first in FY2017-Q1. Latest entry: 2026-10-02.
No other company in this theme has enough history to compare yet.
- FY2024AdvancedAnnual report
「We are also actively pursuing joint research with academic institutions possessing novel drug discovery seeds, making steady progress toward expanding our drug discovery pipeline.」
The company has explicitly stated that it is stepping up joint research with academic institutions possessing novel drug discovery seeds as a means of expanding its drug discovery pipeline. - FY2024-Q3AdvancedAnnual report
「We are also actively pursuing AI-based drug discovery through a specialist team. As a result, in February 2024 we obtained Patent No. 7437558 for technology that enables antibodies to be produced more efficiently by modifying antigens through computer-aided design.」
In AI-based drug discovery, the company obtained a patent in February 2024 for technology to modify antigens using computer-aided design, advancing the intellectual property protection of its drug discovery pipeline. - FY2023AdvancedAnnual report
「In this project, we successfully obtained lead antibodies that could become candidates for next-generation antibody drugs targeting all diseases and have progressed to the development process for next-generation antibody drugs, including small-format antibodies and bispecific antibodies.」
The next-generation antibody program has progressed from successfully obtaining lead antibodies to the development process for small-format antibodies, bispecific antibodies and other products. - FY2023-Q1AdvancedAnnual report
「In June 2022, to further strengthen proteomic analysis, we became the first company in Japan to launch the OlinkⓇ Target contract testing service, which can analyze minute changes in proteins. By combining this proteomic analysis technology with ALAgeneⓇ technology, we aim to strengthen the discovery and identification of drug discovery targets and accelerate the development of the world's first antibody drugs.」
Following the acquisition of アンテグラル's business, the company became the first in Japan to launch the Olink Target contract testing service and gave concrete form to a drug discovery platform combining proteomic analysis with ALAgene technology. - FY2022AdvancedAnnual report
「During the current consolidated fiscal year, we applied and advanced this technology and began producing lead antibodies that could become candidates for next-generation antibody drugs targeting all diseases.」
In addition to advancing ALAgene technology, the five-year AMED research project and the start of lead antibody production, the company is working to shorten the process from target discovery through antibody design with a specialist AI team. - FY2022-Q3AdvancedAnnual report
「To strengthen these antibody drug discovery projects, we acquired the bioscience business of アンテグラル through an absorption-type company split. By combining ALAgeneⓇ technology with proteomic analysis technology, we aim to strengthen the discovery and identification of drug discovery targets and accelerate the development of the world's first antibody drugs. In addition, a specialist team is working to shorten the process from AI-assisted target discovery through antibody design.」
The company acquired the bioscience business of アンテグラル and expanded the means of strengthening its drug discovery pipeline to include combining ALAgene technology with proteomic analysis and shortening the target discovery and antibody design processes using AI. - FY2022-Q1AdvancedAnnual report
「During the first quarter of the current fiscal year, we began developing manufacturing technology for next-generation antibody drugs targeting all diseases by applying and advancing ALAgeneⓇ technology. This R&D project was selected for five years under the FY2021 project of the Japan Agency for Medical Research and Development (AMED), "Drug Discovery Platform Technology Development Project for Realizing Next-Generation Therapies and Diagnostics (Development of Globally Competitive Manufacturing Technology for Next-Generation Antibody Drugs)." During the current fiscal year, we began producing lead antibodies that could become candidates for next-generation antibody drugs.」
The company began developing manufacturing technology for next-generation antibody drugs by applying and advancing ALAgene technology and was selected for five years under an AMED project. It has progressed to the start of lead antibody production. - FY2021AdvancedAnnual report
「In R&D, we newly developed a cocktail ingredient focused on the microbial balance of the scalp. From several dozen ingredients for the scalp environment, we succeeded in identifying the optimal blending ratio for balancing the scalp flora, and the patent for the ingredient was accepted. It has been incorporated into our direct-to-consumer products, creating a framework in which R&D results are rapidly translated into product development.」
The scalp-flora ingredient progressed from patent application to patent acceptance and has been incorporated into direct-to-consumer products. - FY2021-Q3AdvancedAnnual report
「In R&D, we newly developed a cocktail ingredient focused on the microbial balance of the scalp. From several dozen ingredients for the scalp environment, we succeeded in identifying the optimal blending ratio for balancing the scalp flora, and filed a patent application for the ingredient in February 2021. Its adoption in our direct-to-consumer products has been decided, creating a framework in which R&D results are rapidly translated into product development.」
The company developed a cocktail ingredient for balancing the scalp flora and progressed through a patent application in February 2021 to a decision to adopt it in direct-to-consumer products. - FY2021-Q2AdvancedAnnual report
「In particular, for anti-PAD2 antibodies, we are producing humanized antibodies and conducting pharmacological efficacy studies, while advancing partnership discussions with major pharmaceutical companies in Japan and overseas.」
The company outlined specific stages of research at the International PAD Research Center, including the production of humanized anti-PAD2 antibodies and pharmacological efficacy studies, as well as partnership discussions with major pharmaceutical companies in Japan and overseas. - FY2021-Q1AdvancedAnnual report
「In addition, for autoimmune diseases, we established the International PAD Research Center within our Drug Discovery Research Institute, promoted drug discovery research on a range of PAD-related targets, and made steady progress in expanding our drug discovery pipeline.」
The company established the International PAD Research Center within its Drug Discovery Research Institute and set up a framework to advance research on a range of PAD-related targets, progressing the expansion of its autoimmune disease drug discovery pipeline. - FY2020-Q3AdvancedAnnual report
「In R&D, we succeeded in identifying, for the first time in the world, the efficacy of GABA on cognitive function in clinical trials. Its effects on cognitive function, memory and other functions have attracted attention from food and beverage manufacturers as an unprecedented product concept.」
The company confirmed efficacy in a clinical trial targeting cognitive function and has progressed to the stage of developing cognitive function and memory as a new product concept. - FY2020-Q2AdvancedAnnual report
「In particular, we made an active investment in research into the "brain function improvement" properties of PharmaGABAⓇ. Its effects on cognitive function, memory and other functions have already attracted attention in Japan and overseas as an ingredient for new functional food products and products based on an entirely new concept.」
The company has explicitly stated that it is actively investing in research targeting brain function improvement, cognitive function and memory, as well as developing new applications for GABA. - FY2020-Q1RestatedAnnual report
「HGPⓇ (Hair Growth Peptide, HGP), an egg-yolk-derived hair-growth ingredient, is attracting interest as an ingestible hair-growth ingredient unlike conventional products, and adoption by health food manufacturers and others is progressing. CerepronⓇ, a yeast-derived skin-brightening ingredient, is expanding as an ingredient for supplements and cosmetics. The company will continue to pursue further expansion of both ingredients.」
The company continues to report manufacturer adoption of HGP and the expansion of Cerepron’s applications as an ingredient. - FY2019AdvancedAnnual report
「The company has clarified the mechanism underlying HAS-II®’s effects on knee pain, published the findings in a paper, and is working toward compliance with the Foods with Function Claims system.」
A new functional ingredient has progressed to the stage of elucidating and publishing its efficacy mechanism and preparing for compliance with the Foods with Function Claims system. - FY2019-Q3RestatedAnnual report
「HGP (Hair Growth Peptide), an egg-yolk-derived hair-growth ingredient, is seeing increased adoption by distributors and health food manufacturers. It is attracting interest as an ingestible hair-growth ingredient unlike conventional products, and the company will continue to pursue further expansion. In addition, Cerepron, a yeast-derived skin-brightening ingredient, is expanding as an ingredient for supplements and cosmetics, with significant growth focused on Asian markets.」
The company continues to report manufacturer adoption of HGP and the expansion of Cerepron’s applications as an ingredient in Asian markets. - FY2019-Q2RestatedAnnual report
「HGP (Hair Growth Peptide), an egg-yolk-derived hair-growth ingredient, is seeing increased adoption by distributors and health food manufacturers. It is attracting interest as an ingestible hair-growth ingredient unlike conventional products, and the company will continue to pursue further expansion. In addition, Cerepron, a yeast-derived skin-brightening ingredient, is expanding as an ingredient for supplements and cosmetics, with significant growth focused on Asian markets.」
The company continues to report manufacturer adoption of HGP and the expansion of Cerepron’s applications as an ingredient in Asian markets. - FY2019-Q1AdvancedAnnual report
「At ROHTO PHARMACEUTICAL CO.,LTD. in particular, cumulative sales of Senobic exceeded 10 million units, and retail sales at drugstores and other outlets also began, driving further sales growth. In addition, Cerepron, a yeast-derived skin-brightening ingredient, is expanding as an ingredient for supplements and cosmetics, with significant growth focused on Asian markets.」
Cumulative sales of Bonepep-containing products exceeded 10 million units, retail sales also began, and Cerepron grew mainly in Asian markets, indicating progress in the commercialisation of new and functional ingredients. - FY2018-Q3RestatedAnnual report
「HGP has attracted attention from distributors and health food manufacturers as an ingestible hair-growth ingredient, and the company is focusing on securing OEM orders and pursuing further expansion.」
The company continues to pursue the commercialisation and sales expansion of new functional ingredients such as HGP, including manufacturer interest and OEM orders. - FY2018-Q2AdvancedAnnual report
「Bonepep is being developed by ROHTO PHARMACEUTICAL CO.,LTD. and OHAYO DAIRY PRODUCTS CO., LTD. as the Senobic brand of powdered beverage and yogurt, respectively, and the company also worked to expand sales to other domestic manufacturers. HGP has attracted attention from distributors and health food manufacturers as an ingestible hair-growth ingredient, and the company is focusing on securing OEM orders and pursuing further expansion.」
In addition to expanding Bonepep sales to domestic manufacturers, the company reported attention from distributors and health food manufacturers toward HGP and OEM orders, indicating progress in the commercialisation and sales expansion of new ingredients. - FY2018-Q1AdvancedAnnual report
「The supplement Bihatsuness, containing HGP (Hair Growth Peptide), a new egg-yolk-derived hair-growth active ingredient, is being sold by CHARLE CO.,LTD. In addition, the company is developing the new functional ingredient moringa and has begun selling a new moringa-containing supplement through its direct-to-consumer business.」
While continuing to sell HGP-containing products, the company has progressed with moringa, previously under development, to the launch of a supplement containing the ingredient. - FY2017-Q3AdvancedAnnual report
「The company is also conducting research and development on the new functional ingredient moringa and will continue to pursue it actively from both development and sales perspectives to expand revenue in the future.」
In addition to its existing development of new ingredients, the company explicitly identified research and development on moringa and outlined a strategy covering both development and sales. - FY2017-Q2RestatedAnnual report
「In addition, the company is continuing to develop HAS-II, a chicken-cartilage-derived ingredient that promotes hyaluronic acid production, Sarcopep, an egg-white-derived ingredient that inhibits muscle loss, and Cerepron, a yeast-derived skin-brightening ingredient, among others.」
The company is continuing to develop multiple new functional ingredients. - FY2017-Q1AdvancedAnnual report
「Bonepep, an egg-yolk-derived peptide, has been incorporated into Senobic Yogurt, which has newly been launched by OHAYO DAIRY PRODUCTS CO., LTD.」
For Bonepep, one of the ingredients under development, a product containing it has been newly launched, making its commercialisation more concrete. - FY2016-Q3First statedAnnual report
「In addition, the company is pursuing the commercialisation of Banafine, derived from fermented green banana powder, and developing HAS-II, a chicken-cartilage-derived ingredient that promotes hyaluronic acid production, Sarcopep, an egg-white-derived ingredient that inhibits muscle loss, and Cerepron, a yeast-derived skin-brightening ingredient, among others.」
The company is pursuing the commercialisation or development of multiple ingredients with different origins and benefits.